UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~October~~April 3130, ~~2023~~2024

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No.~~333-216645~~

333-216645

VITASPRING BIOMEDICAL CO., LTD.

(Exact name of registrant as specified in its charter)

Nevada

37-1836726

State or other jurisdiction of

Incorporation or organization

(IRS Employer

Identification No.)

5225 Canyon Crest Drive,

Suite 71-802, Riverside, CA

92507

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code (949) 202-9235

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

None

N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant as required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐ Yes ☒ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

Indicate by checkmark whether the issuer has filed all documents and reports required to be filed by Section 12, 13 and 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. ☐ Yes ☐ No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the most practicable date:

Class		Outstanding as of January 19, 2026
Common Stock, $0.0001		207,030,030

As of March 31, 2026, the registrant had 207,030,030 shares of common stock issued and outstanding.

TABLE OF CONTENTS

	PART I – FINANCIAL INFORMATION	Page No.
Item 1	Financial Statements (Unaudited)	3
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3	Quantitative and Qualitative Disclosures about Market Risk	9
Item 4	Controls and Procedures	910
	PART II – OTHER INFORMATION
Item 1	Legal Proceedings	1112
Item 1A	Risk Factors	1112
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	1117
Item 3	Defaults Upon Senior Securities	1117
Item 4	Mine Safety Disclosures	1117
Item 5	Other Information	1117
Item 6	Exhibits	1217

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

VITASPRING BIOMEDICAL CO., LTD.

INDEX TO FINANCIAL STATEMENTS

Balance Sheets (unaudited)		F-1
Statements of Operations (unaudited)		F-2
Statement of Changes in Stockholders’ Equity (Deficit) (unaudited)		F-3
Statements of Cash Flows (unaudited)		F-4
Notes to the Unaudited Financial Statements		F-5 - F-1314

Table of Contents

VITASPRING BIOMEDICAL CO., LTD

BALANCE SHEETS

(Unaudited)

	October 31,			January 31,
	April 30,			January 31,
	2023			2023
	2024			2024
ASSETS
CURRENT ASSETS
Cash	$	~~2,636~~968		$	~~29,656~~13
Accounts receivable, net of allowance for credit loss accounts of $33,632		60,000			380,000
Prepaid expenses		39,725			-
Prepaid expenses		5,364			27,422
Deposits		23,614			23,614
Deposits		38,308			-
Total current assets		64,307			23,627
Total current assets		106,308			437,078
LONG-TERM ASSETS
Equipment, net		38,277			49,574
Equipment and vehicle, net		21,574			24,063
Operating lease right-of-use asset		~~132~~45,~~764~~407			~~255~~89,~~682~~652
Deposits		-			23,614
Total long-term assets		66,981			113,715
Total long-term assets		171,041			328,870
Total assets	$	131,288		$	137,342
Total assets	$	277,349		$	765,948
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable - related party	$	2,411,000		$	2,411,000
Accounts payable and other payables		~~316~~279,~~507~~056			55339,~~063~~001
Income tax payable		218,714			218,714
Operating lease liabilities		~~138~~47,~~287~~248			~~169~~93,~~647~~334
Advances from related party		358,849			214,682
Advance from related party		701,073			425,482
Total current liabilities		3,443,357			3,069,106
Current liabilities and total liabilities		3,657,091			3,487,531
LONG-TERM LIABILITY
Operating lease liabilities, net of current		-			93,334
Total long-term liability		-			93,334
Total liabilities		3,443,357			3,162,440
COMMITMENTS AND CONTINGENCIES		-			-
STOCKHOLDERS' DEFICIT
Common stock, $0.0001 par value, 500,000,000 shares authorized 207,030,030 shares issued.		20,703			20,703
Additional paid-in capital		1,~~094~~176,~~472~~906			~~970~~1,~~824~~135,689
Accumulated deficit		(4,~~281~~723,~~183~~412	)		(34,~~388~~506,~~019~~581	)
Total stockholders' deficit		(3,~~166~~525,~~008~~803	)		(23,~~396~~350,~~492~~189	)
Total liabilities and stockholders' deficit	$	~~277~~131,~~349~~288		$	~~765~~137,~~948~~342

See the accompanying Notes, which are an integral part of this unaudited financial statement.

F-1

Table of Contents

VITASPRING BIOMEDICAL CO., LTD

STATEMENTS OF OPERATIONS

(Unaudited)

	Three months ended						~~Nine months ended~~
	October 31,						October 31,
	April 30,
	2023			2022			2023			2022
	2024			2023
Revenues	$	-		$	-		$	-		$	~~1,490,000~~
Cost of goods sold		-			-			-			922,000
Operating Expenses
Gross profit		-			-			-			568,000
Selling, general and administrative expenses		216,831			304,601
Operating Expenses
Loss from operations		(216,831	)		(304,601	)
Selling, general and administrative expenses		234,980			183,219			893,164			582,603
Net loss from operations before provision for income taxes		(216,831	)		(304,601	)
Loss from operations		(234,980	)		(183,219	)		(893,164	)		(14,603	)
Provision for income tax expense		-			-
Other income (expense)
Net loss	$	(216,831	)	$	(304,601	)
Other income (expense)		-			(637	)		-			7,935
Net loss per share: Basic and diluted		(0.00	)		(0.00	)
Total other income (expense)		-			(637	)		-			7,935
Weighted average number of shares outstanding: Basic and diluted		207,030,030			207,030,030
Loss income from operations before provision for income taxes		(234,980	)		(183,856	)		(893,164	)		(6,668	)
Provision for income tax expense (benefit)		-			(45,575	)		-			(908	)
Net loss	$	(234,980	)	$	(138,281	)	$	(893,164	)	$	(5,760	)
Net loss per share: Basic and diluted		(0.00	)		(0.00	)		(0.00	)		(0.00	)
Weighted average number of shares outstanding: Basic and diluted		207,030,030			206,520,030			207,030,030			206,520,030

See the accompanying Notes, which are an integral part of this unaudited financial statement.

F-2

Table of Contents

VITASPRING BIOMEDICAL CO., LTD

STATEMENTS OF CHANGES IN STOCKHOLDERS’ ~~EQUITY (~~DEFICIT)

(Unaudited)

For the three ~~and nine~~ months ended ~~October~~April 3130, ~~2023~~2024

					Additional					Total
	Common Stock				Additional		Accumulated			Total
	Common Stock				paid-in		Accumulated			Stockholders'
	Number of shares		Amount		Paid-in Capital		Deficit			Stockholders' Deficit
	Number of shares		Amount		capital		Deficit			Deficit
Balance, January 31, 2024		207,030,030	$	20,703	$	1,135,689	$	(4,506,581	)	$	(3,350,189	)
Balance, January 31, 2023		207,030,030	$	20,703	$	970,824	$	(3,388,019	)	$	(2,396,492	)
Stock-based compensation		-		-		41,217		-			41,217
Stock-based compensation		-		-		41,216		-			41,216
Net loss		-		-		-		(216,831	)		(216,831.00	)
Net loss		-		-		-		(304,601	)		(304,601	)
Balance, April 30, 2024		207,030,030	$	20,703	$	1,176,906	$	(4,723,412	)	$	(3,525,803	)
Balance, April 30, 2023		207,030,030	$	20,703	$	1,012,040	$	(3,692,620	)	$	(2,659,877	)
Stock-based compensation		-		-		41,216		-			41,216
Net loss		-		-		-		(353,583	)		(353,583	)
Balance, July 31, 2023		207,030,030	$	20,703	$	1,053,256	$	(4,046,203	)	$	(2,972,244	)
Stock-based compensation		-		-		41,216		-			41,216
Net loss		-		-		-		(234,980	)		(234,980.00	)
Balance, October 31, 2023		207,030,030	$	20,703	$	1,094,472	$	(4,281,183	)	$	(3,166,008	)

For the three ~~and nine~~ months ended ~~October~~April 3130, ~~2022~~2023

					Additional					Total
	Common Stock				Additional					Total
	Common Stock				paid-in					Stockholders'
	Number of shares		Amount		Paid-inCapital		AccumulatedDeficit			Stockholders'Deficit
	Number of shares		Amount		capital		Retained earnings			Equity
Balance, January 31, 2023		207,030,030	$	20,703	$	970,824	$	(3,388,019	)	$	(2,396,492	)
Balance, January 31, 2022 - restated		206,520,030	$	20,652	$	780,510	$	776,377		$	1,577,539
Stock-based compensation		-		-		41,216		-			41,216
Stock-based compensation		-		-		36,509		-			36,509
Net loss		-		-		-		(304,601	)		(304,601	)
Net income		-		-		-		276,656			276,656
Balance, April 30, 2023		207,030,030	$	20,703	$	1,012,040	$	(3,692,620	)	$	(2,659,877	)
Balance, April 30, 2022		206,520,030	$	20,652	$	817,019	$	1,053,033		$	1,890,704
Stock-based compensation		-		-		36,509		-			36,509
Net loss		-		-		-		(144,135	)		(144,135	)
Balance, July 31, 2022		206,520,030	$	20,652	$	853,528	$	908,898		$	1,783,078
Stock-based compensation		-		-		36,509		-			36,509
Net loss		-		-		-		(138,281	)		(138,281	)
Balance, October 31, 2022		206,520,030	$	20,652	$	890,037	$	770,617		$	1,681,306

See the accompanying Notes, which are an integral part of this unaudited financial statement.

F-3

Table of Contents

VITASPRING BIOMEDICAL CO., LTD

STATEMENTS OF CASH FLOWS

(Unaudited)

	Nine months ended
	Three Months ended
	October 31,
	April 30,
	2023			2022 (Restated)
	2024			2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$	(893,164	)	$	(5,760	)
Net loss	$	(216,831	)	$	(304,601	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		112,~~297~~489			113,~~297~~766
Non-cash lease expense		~~122~~44,~~918~~245			~~137~~39,~~554~~953
Stock-based compensation		~~123~~41,~~648~~217			~~109~~41,~~527~~216
Deferred tax benefit		-			(1,708	)
Changes in assets and liabilities:
Accounts receivable		~~320,000~~-			~~931~~150,~~890~~000
Prepaid expenses		22(39,~~058~~725	)		(211,~~925~~716	)
Deposits		~~(14,694~~-	)		-(14,694	)
Accounts payable and other payables		261,444			(1,251,500	)
Payroll liability		-			33,030
Change in operating lease liability		(124,694	)		(133,938	)
Accounts payable and other payables		(59,945	)		-
Income tax payable		-			800
Change in operating lease liability		(46,086	)		(39,920	)
Advances from related party for operating expense		138,890			121,601
Advances from the related party for operating expense		270,613			51,594
Net cash used in operating activities		(324,~~297~~023	)		(8327,~~162~~940	)
CASH FLOWS FROM FINANCING ACTIVITY
Advances from related parties		5,277			-
Advances from Related party		4,978			1,277
Net cash provided by financing activity		54,~~277~~978			-1,277
Net change in cash		~~(27,020~~955	)		(8326,~~162~~663	)
Cash at beginning of period		~~29,656~~13			~~107~~29,~~212~~656
Cash at end of period	$	~~2,636~~968		$	242,~~050~~993
Supplemental cash flow disclosures:
Income taxes paid	$	-		$	-
Interest expense paid	$	-		$	-
Non-cash investing and financing activities
Stock-based compensation for restricted common shares	$	~~123~~41,~~648~~217		$	~~109~~41,~~527~~216

See the accompanying Notes, which are an integral part of this unaudited financial statement.

F-4

Table of Contents

VITASPRING BIOMEDICAL CO., LTD.

Notes to Unaudited Financial Statements

~~October~~April 3130, ~~2023~~2024

Note 1 – ORGANIZATION AND NATURE OF ~~BUSINESSR~~BUSINESS

VitaSpring Biomedical Co., Ltd (“the Company”) was incorporated in the State of Nevada on September 6, 2016. The Company aims to build a cell medical industry, invest in research and development of stem cell applications in regenerative medicine, establish advanced medical research centers and high -standard cell production centers, and provide “GTP” standard stem cell preparations for the development of cellular drugs. Through the development of cell medicine, it will become a leading international business group in the fields of regenerative medicine applied to the innovative fields of medicine, preventive health care, beauty, and anti-aging. The “GTP Cell Center” is the basis for its business, which is cross-domain in biotechnology, medical treatment, medicine and medical materials, and focuses on the development of cell medical treatment.

Note 2 – GOING CONCERN

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. ~~The~~As of April 30, 2024, the Company ~~incurred~~had ancash ~~accumulated~~of ~~deficit~~$968, total current assets of $464,~~281~~307,~~183~~ and ~~working~~total ~~capital~~current ~~deficiency~~liabilities of $3,~~337~~657,~~049 as of October 31~~091, ~~2023~~resulting ~~and~~in a ~~negative~~working ~~cash~~capital ~~flow~~deficit ~~from~~of ~~operations amounting to~~ $323,~~297 for nine months ended October 31~~592, ~~2023~~784. ~~There~~The ~~is substantial doubt about the~~ Company’s ~~ability~~incurred toa ~~continue~~net asloss aof ~~going~~$216,831 and ~~concern~~negative ~~due~~cash toflows ~~the~~from ~~limited~~ operating ~~history~~activities of ~~the business. There can be no assurance that the Company will achieve or maintain profitability. Management anticipates that the Company will be dependent~~$4, 023 for the ~~near~~three ~~future,~~months onended ~~additional~~April ~~investment~~30, ~~capital to fund operating expenses~~2024. The Company ~~intends~~also tohas ~~position~~an ~~itself~~accumulated sodeficit ~~that it will be able to raise additional funds through the capital markets. In light~~ of ~~management’s efforts~~$4,723,412 as ~~there are no assurances that the Company will be successful in this or any~~ of ~~its~~April ~~endeavors~~30, ~~or become financially viable and continue as a going concern~~2024.

The Company’s minimal cash balance, recurring operating losses, and significant working capital raise substantial doubt about its ability to continue as a going concern within one year after the financial statements are issued. The Company has historically financed its operations through advances from related parties and equity issuances. Management plans to continue seeking additional capital through equity financing, strategic partnerships, and related-party support in order to fund operating expenses and meet its obligations as they become due. However, there can be no assurance that such financing will be available on acceptable terms, or at all.

The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Note 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim period presented, have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10K filed with the SEC on ~~December~~January 131, ~~2025~~2026, have been omitted.

Segment Reporting

The Company operates in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 280, Segment Reporting, which establishes standards for reporting information about operating segments in financial statements.

The Company’s chief operating decision maker (“CODM”), who is the Chief Executive Officer, regularly reviews consolidated financial information to make operating decisions, allocate resources, and assess performance. The CODM does not evaluate the business on a disaggregated basis, and discrete financial information is not available by product line, service, or geographic location. The CODM evaluates performance based on net loss and cash position.

As a result, the Company has determined that it operates as a single operating and reportable segment. All revenues are generated from a single line of business and substantially all long-lived assets are located in the United States. Accordingly, no additional segment disclosures are required.

F-5

Table of Contents

As a result, the Company has determined that it operates as a single operating and reportable segment. All revenues are generated from a single line of business, and substantially all long-lived assets are located in the United States. Accordingly, no additional segment disclosures are required.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions, that affect the reported amounts of assets, liabilities, ~~revenues,~~the ~~and expenses, and~~ disclosure of contingent assets and liabilities at the date the financial statements., ~~Actual~~and ~~results~~reported ~~could~~amounts ~~differ~~of ~~from~~revenues ~~those~~and ~~estimates.~~expenses ~~For~~during the ~~nine~~period. ~~months~~Significant ~~ended~~estimates ~~October~~include, 31but are not limited to, ~~2023~~stock-based compensation, ~~the~~lease ~~Company’s~~liabilities, ~~operations~~allowance ~~and~~for ~~financial~~credit ~~statement~~losses, ~~items~~and ~~did~~the ~~not~~assessment ~~require~~of the ~~use~~Company’s ofability ~~any~~to ~~significant~~continue ~~estimates~~as ora ~~assumptions~~going concern. ~~All~~Management ~~amounts~~bases ~~presented~~its ~~are~~estimates ~~based~~ on ~~actual~~historical experience, ~~readily~~current ~~determinable values~~conditions, and novarious ~~material~~other ~~judgments~~assumptions orthat ~~estimation~~are ~~methodologies~~believed ~~were~~to ~~applied~~be reasonable under the circumstances. Actual results could materially differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company ~~did~~had ~~not~~no ~~have any~~ cash equivalents as of ~~October~~April 3130, ~~2023~~2024, and January 31, ~~2023~~2024.

Allowance for Credit Loss

Effective February 1, 2022, the Company adopted Accounting Standards Update (ASU) 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires entities to estimate expected credit losses over the life of financial assets measured at amortized cost using a current expected credit loss (CECL) model. The adoption did not have a material impact on the Company’s financial statements.

The allowance for credit losses represents management’s estimate of expected credit losses related to accounts receivable. The Company evaluates the collectability of its accounts receivable based on historical experience, the aging of receivables, and specific customer credit risk, in accordance with the CECL model.

Accounts deemed uncollectible are written off against the allowance when collection efforts have been exhausted. For the fiscal year ended January 31, 2023, the Company established a reserve for credit losses of $33,632 and recognized an equivalent amount as bad debt expense. The reserve was based on outstanding accounts receivable from customers who had ceased operations, filed for bankruptcy, or exhibited significant financial difficulties. As of April 30, 2024, and January 31, 2024, the allowance for credit losses was $33,632.

Accounts Receivable, Net

Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company maintains an allowance for credit loss accounts for estimated losses that may result from the inability of customers to make required payments.

The ~~allowance~~following ~~for~~table ~~credit~~presents ~~losses~~the ~~represents~~gross ~~management’s~~accounts ~~estimate~~receivable, ofallowance ~~expected~~for credit ~~losses~~loss, ~~related~~and tonet accounts receivable. ~~The~~as ~~Company evaluates the collectability~~ of ~~its~~April ~~accounts receivable based on historical experience~~30, ~~the aging of receivables~~2024, and ~~specific~~January ~~customer credit risk~~31, ~~in accordance with the CECL model~~2024.

Accounts deemed uncollectible are written off against the allowance when collection efforts have been exhausted. For the three and nine months ended October 31, 2023 and 2022, the Company did not establish a reserve for credit losses and recognize an equivalent amount as bad debt expense. The reserve was based on outstanding accounts receivable from customers who had ceased operations, filed for bankruptcy, or exhibited significant financial difficulties. As of October 31, 2023 and January 31, 2023, the allowance for credit losses was $33,632.

	April 30,			January 31,
	2024			2024
Accounts receivable - Gross	$	33,632		$	33,632
Less: Allowance for credit loss		(33,632	)		(33,632	)
Accounts receivable - net	$	-		$	-

~~The~~F-6 ~~following~~Table ~~table presents the gross accounts receivable, allowance for credit loss, and net accounts receivable as~~ of ~~October 31, 2023 and January 31, 2023.~~Contents

	October 31,			January 31,
	2023			2023
Accounts receivable - Gross	$	93,632		$	413,632
Les: Allowance for credit loss		(33,632	)		(33,632	)
Accounts receivable - net	$	60,000		$	380,000

In addition, the Company collected $60,000 in accounts receivable related to fiscal year 2023 transactions in November 2023.

Prepaid Expenses

Prepaid expenses are recorded at cost, net of amortization.

Impairment of Long-lived Assets

Long-lived assets with finite lives, primarily property and equipment, intangible assets, and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated cash flows from the use of the asset and its eventual disposition are below the asset’s carrying value, then the asset is deemed to be impaired and written down to its fair value. No impairment charges were recorded during the three months ended April 30, 2024, or 2023.

Equipment, Depreciation, Amortization, and Capitalization

Equipment and vehicles are stated at cost. The Company records depreciation and amortization when appropriate using the straight-line method over the estimated useful life of the assets. The Company estimates that the useful life of necessary equipment is 3-5 years and vehicle is 5 years. Expenditures for maintenance and repairs are charged to expense as incurred. Additions, major renewals, and replacements that increase the vehicles and equipment’s useful life are capitalized. ~~Equipment~~Vehicle and equipment sold or retired, together with the related accumulated depreciation, isare removed from the appropriate accounts and the resultant gain or loss is included in net income (loss). During the year ended January 31,2024, the Company recognized impairment of furniture and equipment and computers of $10,449. During the three months ended April 30, 2024 and 2023, the Company recognized depreciation of $2,489 and $3,706, respectively.

~~F-6~~As ~~Table~~of April 30, 2024, and January 31, 2024, a vehicle and equipment consisted of ~~Contents~~the following:

The Company reviews long-lived assets, including equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If such indicators are present, the Company compares the estimated undiscounted future cash flows expected to result from the use and eventual disposition of the asset group to its carrying amount. If the carrying amount exceeds the estimated future cash flows, an impairment loss is recognized in the amount by which the carrying value exceeds the fair value of the asset group. No impairment charges were recorded during the three and nine months ended October 31, 2023 or 2022.

	April 30,			January 31,
	2024			2024
Vehicle	$	49,785		$	49,785
Furniture and equipment		19,741			19,741
Computers		3,471			3,471
		72,997			72,997
Accumulated depreciation		(40,974	)		(38,485	)
Accumulated impairment		(10,449	)		(10,449	)
Total vehicle and equipment, net	$	21,574		$	24,063

As of October 31, 2023 and January 31, 2023, equipment consisted of the following:

	October 31,			January 31,
	2023			2023
Vehicle	$	49,785		$	49,785
Furniture and equipment		19,741			19,741
Computer		3,471			3,471
		72,997			72,997
Accumulated depreciation		(34,720	)		(23,423	)
Total equipment, net	$	38,277		$	49,574

Accounts Payable

The Company recognizes accounts payable when obligations arise from the receipt of goods and services in the ordinary course of business. Accounts payable are recorded at cost and represent amounts owed to vendors and service providers that are non-interest -bearing and typically settled within standard payment terms.

The Company regularly evaluates accounts payable balances ~~regularly~~ to ensure completeness and accuracy and ~~consider~~considers all amounts ~~to be~~ current unless otherwise specified. Any significant accrued liabilities for services received but not yet invoiced are included in accrued expenses within the balance sheet.

All accounts payable are classified as current liabilities. The Company did not incur any material interest or penalties on past due balances during the periods presented.

As of April 30, 2024, and January 31, 2024, the Company’s accounts payable – related party totaled $2,411,000.

F-7

Table of Contents

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers”. The core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity recognizes revenue in accordance with that core principle by applying the following steps: Step 1: Identify the contract(s) with a customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price to the performance obligations in the contract Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. Specifically, Section 606-10-50 requires an entity to provide information about: a. Revenue recognized from contracts with customers, including the disaggregation of revenue into appropriate categories; b. Contract balances, including the opening and closing balances of receivables, contract assets, and contract liabilities; c. Performance obligations, including when the entity typically satisfies its performance obligations and the transaction price that is allocated to the remaining performance obligations in a contract; d. Significant judgments, and changes in judgments, made in applying the requirements to those contracts.

More specifically, the Company contracts with its suppliers (“Vendor”) to buy a specific number of stem cells and exosomes at agreed-upon prices. The Company must pay for those stem cells regardless of whether it is able to resell them. A customer (“Buyer”) generally visits the Company’s website searching for available stem cells and exosomes, obtains a price quotation, and places an order with the Company, ~~who~~which then confirms the purchase order, as a contract with that particular Buyer. The Company has discretion in establishing the prices for the stem cells it sells to the Buyer.

~~F-7~~The ~~Table~~Company obtains control of ~~Contents~~the stem cell (which it could resell) when stored at a separate/specified liquid nitrogen tank at the Vendor and transfers that product to the Buyer. The common delivery term is Ex Works Warehouse. The Company assists the Buyer in resolving product issues including complaints with the products provided by the Vendor. The Vendor is responsible for fulfilling the obligations associated with the transfer of the stem cell purchased, including coordination with cold chain shipping companies when required. The Company is the principal for the sale of the stem cell to the Buyer and recognizes revenue upon shipment by the Vendor to the Buyer, upon shipping/delivery confirmation. The revenue is recognized on a gross basis. The specified good is a selected type of stem cell, along with the other exosomes provided by the Vendor for the Buyer of that stem cell. The following are indications of control by the Company:

The Company obtains control of the stem cell (which it could resell) when stored at a separate/specified liquid nitrogen tank at the Vendor and transfers that product to the Buyer. The common delivery term is Ex Works Warehouse. The Company assists the Buyer in resolving product issues including complaints with the products provided by the Vendor. The Vendor is responsible for fulfilling the obligations associated with transfer of the stem cell purchased, including coordination with cold chain shipping companies when required. The Company is the principal for the sale of the stem cell to the Buyer and recognizes revenue upon shipment by the Vendor to the Buyer, upon shipping/delivery confirmation. The revenue is recognized on a gross basis. The specified good is a selected type of stem cell along with the other exosome provided by the Vendor for the Buyer of that stem cell. The following are indications of control by the Company:

	·	The Vendor is responsible for manufacturing the products, while the Company retains primary responsibility for fulfilling the obligation to deliver the products from the Vendor’s separate storage facility to the Buyer.

	·	The Company has inventory risk as a result of purchasing the stem cells from the Vendor and will be subject to the risks and rewards of ownership, including loss if it is unable to sell the stem cells.

	·	The Company has the discretion in establishing the selling price of the stem cells for its contract with the Buyers.

	·	In Summary, the Company is primarily responsible for fulfillment, inventory risk, and pricing discretion. The Company recognizes revenue equal to the price to be paid by the Buyer for the stem cells upon transfer of control of the stem cells to the Buyer. The Company recognizes the cost of the stem cells at the purchase price to be paid to the Vendor, as cost of sales, upon purchase from the Vendor.

Cost of Goods Sold

Cost of goods sold includes all direct costs related to the production or purchase of the Company’s products. These costs primarily consist of raw materials, direct labor, and manufacturing overhead, including depreciation of production equipment, inbound freight, packaging, and other production-related expenses.

Income Taxes

There are inherent uncertainties related to the interpretation of tax regulations in the jurisdictions in which the Company transacts business. The judgments and estimates made at a point in time may change based on the outcome of tax audits, as well as changes to, or further interpretations of, regulations. The Company adjusts its income tax expense in the period in which these events occur. If such changes take place, there is a risk that the tax rate may increase or decrease in any period.

F-8

Table of Contents

The FASB guidance contained in ASC Topic 740, Income Taxes, addresses the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a threshold of “more likely than not” for recognition and derecognition of tax positions taken or expected to be taken in a tax return.

The Company adopted this guidance and is now required to recognize the effect of income tax positions only if those positions are more likely than not of be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being recognized. Additionally, previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first financial reporting period in which that threshold is no longer met. Changes in recognition or measurement will be reflected in the period in which the change in judgment occurs.

F-8 Table of Contents

The Company’s income tax filings are subject to audit by various taxing authorities. The Company’s open audit periods are three years for federal and four years for California. In evaluating the Company’s tax provisions and accruals, future taxable income, and the reversal of temporary differences, interpretations, and tax planning strategies are considered. The Company had no material adjustments to its liabilities for unrecognized income taxes under the guidelines of the ASC Topic 740 for uncertainty in income taxes and believes their estimates are appropriate based on current facts and circumstances.

Fair Value of Financial Instruments

ASC topic 820 “Fair Value Measurements and Disclosures” establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

These tiers include:

Level 1:	defined as observable inputs such as quoted prices in active markets;
Level 2:	defined as inputs other than quoted prices in active markets that are either directly or indirectly observable;
Level 3:	defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The carrying value of cash and the Company’s loan from shareholders approximates its fair value due to their short-term maturity.

Basic (Loss) Income Per Share

The Company computes income (loss) per share in accordance with FASB ASC 260 “Earnings per Share”. Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period.

Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares when their inclusion would be anti-dilutive. AsFor ofthe ~~October~~three ~~31,~~months ~~2023~~ended ~~and~~April ~~January~~30, 312024, and 2023, ~~there~~the following common stock equivalents were noexcluded ~~potentially~~from ~~dilutive~~the ~~debt~~computation orof ~~equity~~diluted ~~instruments~~net ~~issued~~loss orper ~~outstanding~~share as the result of the computation was anti-dilutive.

	Three Months Ended
	April 30,
	2024		2023
	Shares		Shares
Unvested restricted common stock		32,972,900		65,945,800

F-9

Table of Contents

Stock-Based Compensation

The Company measures all stock-based awards granted to employees, directors and non-employees based on the fair value on the date of grant in accordance with ASC 718, Compensation – Stock Compensation. The compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. Generally, the Company issues awards with either service-only vesting conditions and records the expense using the straight-line method or service and performance vesting conditions and records the expense when achievement of the performance condition becomes probable using the graded-vesting method. The Company accounts for forfeitures as they occur.

The fair value of stock-based grant awards is estimated using the fair value of the Company’s most recent historical transaction with third parties, is arm’s-length and requires management judgment. The Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.

Foreign Currency Translation

The Company’s functional and reporting currency is the U.S. dollar. Transactions may occur in foreign currencies and management has adopted ASC 830, “Foreign Currency Translation Matters.” Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Average monthly rates are used to translate revenues and expenses. Gains and losses arising on translation or settlement of foreign currency -denominated transactions or balances are included in selling, general and administrative expenses in the statement of operations.

F-9 Table of Contents

Leases

The Company determines whether a contract is or contains a lease at contract inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities on our balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities on the Company’s balance sheets.

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As most of the Company’s leases do not provide an implicit rate, we use the Company’s incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense for fixed lease payments is recognized on a straight-line basis over the lease term. Variable lease payments are generally expensed as incurred and may include certain index-based changes in rent and other non-fixed payments for services provided by the lessor. The Company’s leases do not contain any material residual guarantees or material restrictive covenants.

Lease arrangements with lease and non-lease components are generally accounted for separately. For certain equipment leases, such as vehicles, the Company will account for the lease and non-lease components as a single lease component. Additionally, for certain equipment leases, the Company will apply a portfolio approach to effectively account for the operating lease ROU assets and liabilities.

Recently Issued Accounting Pronouncements

In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurements of Credit Losses for Accounts Receivable and Contract Assets (ASU 2025-05). The amendments in this update provide a practical expedient ~~related~~for toestimating ~~the estimation of~~ expected credit losses ~~for~~on current accounts receivable and current contract assets ~~that~~arising ~~arise~~ from transactions accounted for under ASC 606. Under ASU 2025-05, an entity is required to disclose whether it has elected to use the practical expedient. An entity that makes the accounting policy election is required to disclose the date through which subsequent cash collections are evaluated. ASU 2025-05 is effective for the Company beginning in the fiscal year ending December 31, 2026. The Company is currently evaluating the impacts of the adoption of ASU 2025-05 on the Consolidated Financial Statements.

In May 2025, the FASB issued ASU 2025-04 Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to Share-Based Consideration Payable to a Customer (“ASU 2025-04”) which clarifies the guidance on the accounting for share-based payment awards that are granted by an entity as consideration payable to its customer, with the intent to reduce diversity in practice and improve existing guidance by revising the definition of a “performance condition” and eliminating a forfeiture policy election for service conditions associated with share-based consideration payable to a customer. It also clarifies the guidance in Topic 606 on the variable consideration constraint does not apply to share-based consideration payable to a customer “regardless of whether an award’s grant date has occurred”. ASU 2025-04 will be effective for the annual periods beginning after December 15, 2026 with early adoption permitted. The Company does not believe ASU 2025-04 will have a material impact on its financial position, results of operations or financial statement disclosure.

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.

F-10

Table of Contents

In May 2025, the FASB issued ASU 2025-04 Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to Share-Based Consideration Payable to a Customer (“ASU 2025-04”) which clarifies the guidance on the accounting for share-based payment awards that are granted by an entity as consideration payable to its customer, with the intent to reduce diversity in practice and improve existing guidance by revising the definition of a “performance condition” and eliminating a forfeiture policy election for service conditions associated with share-based consideration payable to a customer. It also clarifies the guidance in Topic 606 on the variable consideration constraint does not apply to share-based consideration payable to a customer “regardless of whether an award’s grant date has occurred”. ASU 2025-04 will be effective for the annual periods beginning after December 15, 2026, with early adoption permitted. The Company does not believe ASU 2025-04 will have a material impact on its financial position, results of operations or financial statement disclosure.

In March 2024, the FASB issued ASU 2024-02 "Codification Improvements – Amendments to Remove References to the Concepts Statements" ("ASU 2024-02"), which contains amendments to the Codification to remove references to various FASB Concepts Statements. In most instances, the references are extraneous and not required to understand or apply the guidance. Generally, ASU 2024-02 is not intended to result in significant accounting changes for most entities. ASU 2024-02 is effective for the Company for fiscal years beginning after December 15, 2024. The Company does not expect this update to have a material impact on its financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which ~~requires~~require, among other things, additional disclosures primarily related to the income tax rate reconciliation and income taxes paid. The expanded annual disclosures are effective for our year ending December 31, 2025. The Company is currently evaluating the impact that ASU 2023-09 will have on our consolidated financial statements and whether we will apply the standard prospectively or retrospectively.

The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

Note 4 – Related Party Transactions and Balances

Advances from Related Party

During the ~~nine~~three months ended ~~October~~April 3130, ~~2023~~2024, and ~~2022~~2023, the Company received advances totaling $54,~~277~~ 978 and $0 1,277 from Cheng-Hsiang Kao, the Company’s previous Chief Executive Officer who is also a major shareholder and operating expenses of $~~138~~270,~~890~~ 613 and $~~121~~51,~~601~~ 594 were paid on behalf of the Company. These advances are unsecured, non-interest -bearing, and payable on demand. As of ~~October~~April 3130, ~~2023~~2024, and January 31, ~~2023~~2024, the total amount of shareholder advances outstanding was $~~358~~701,~~849~~ 073 and $~~214~~425,~~682~~282, respectively.

Due to Related Party

The Company sources its inventory exclusively from a vendor wholly owned by shareholders who collectively hold more than 20% of the Company’s outstanding common shares as of ~~October~~April 3130, ~~2023~~2024. These shareholders are also family members of the Company’s Chairman. As of ~~October~~April 3130, ~~2023~~2024, and January 31, ~~2023~~2024, amounts due to this related party totaled $2,411,000 are disclosed in Accounts Payable – related party on the balance sheets.

F-11

Table of Contents

Note 5 – EQUITY

Common Stock

The number of authorized shares of common stock under the Certificate of Incorporation is 500,000,000, $0.~~001~~ 0001 par value.

During the three ~~and nine~~ months ended ~~October~~April 3130, 2024, and 2023, the Company did not issue any shares of common stock.

Stock-based compensation

The Company’s stock-based compensation programs are long-term retention programs that are intended to attract, retain and provide incentives for employees, officers and directors, and to align stockholder and employee interests.

Under the stock-based compensation plan, the Company may grant Incentive Stock Options (“ISO”), Non-statutory Stock Options (“NSO”), Restricted Stock (“RS”) and Restricted Stock Units (“RSU). ISO and NSO are granted under service conditions. RS and RSU are granted under vesting criteria set by the Administrator and could be based upon the achievement of Company-wide, business unit, or individual goals (including, but not limited to, continued employment or service), or any other basis determined by the Administrator in its discretion. Stock options granted to employees generally vest over a four-year period, although certain grants may vest over a longer or shorter period. Stock options granted to non-employees generally vest over a one-year period.

F-11 Table of Contents

Valuation of Stock-Based Compensation

Stock-based compensation cost is measured at the grant date based on the fair value of the award. The fair value of the awards is fixed at the grant date and amortized over the longer of the remaining performance or service period. The fair value of stock-based grant awards is estimated using the fair value of the Company’s most recent historical transaction with third parties.

Compensation costs

The Company recognizes the estimated compensation cost of all stock-based awards generally on a straight-line basis over the requisite service period of the entire award, which is generally the vesting period. The estimated compensation cost is based on the fair value of the common stock on the date of the grant. The Company accounts for forfeitures as they occur.

131,901,600 restricted common shares, granted on October 4, 2020, at a fair value of $0.005 per share, are vested over 4 fiscal years equally (vesting period) commencing on October 4, 2020.

Common stock activities for the ~~nine~~three months ended ~~October~~April 3130, ~~2023~~2024, are summarized as follows:

	Number ofShares		Weighted AverageRemaining ContractualLife (Years)		Weighted AverageGrant DateFair Value
			Weighted Average		Weighted
January 31, 2023		65,945,800		1.7	$	0.005
			Remaining		Average
Vested		32,972,900		-		-
	Number of		Contractual Life		Grant Date
October 31, 2023 - Expected to Vest		32,972,900		0.9	$	0.005
	Shares		(Years)		Fair Value
January 31,2024		32,972,900		0.7	$	0.005
Vested		-		-		-
April 30, 2024- Expected to Vest		32,972,900		0.4	$	0.005

As of ~~October~~April 3130, ~~2023~~2024, there was $~~151~~68,~~126~~ 694 of unrecognized compensation cost related to non-vested stock-based awards, to be recognized over a weighted average period of 0.92 4 years.

Stock-based compensation recognized for ~~nine~~the three months ended ~~October~~April 3130, ~~2023 and 2022 amounted to $123~~2024,~~648~~ and ~~$109,527, respectively. Stock-based compensation recognized for three months ended October 31,~~ 2023 ~~and 2022~~ amounted to $41,~~216~~ 217 and $3641,~~509~~216, respectively.

F-12

Table of Contents

Note 6 – OPERATING LEASES

In July 2021, the Company entered into a non-cancelable operating lease for an office facility in Irvine, California. The lease agreement requires 36 monthly lease payments that range from $14,796 to $16,013 per month. The lease commences in August 2021 and expires in July 2024. The lease has a remaining lease term of less than three years, with no options to extend. In August 2024, the lease agreement for the Company’s office facility in Irvine, California expired. The Company elected not to renew the lease.

There are no lease transactions classified as finance leases for the ~~nine~~three months ended ~~October~~April 3130, ~~2023~~2024.

The table below summarizes the components of operating lease costs related to operating leases for the three ~~and nine~~ months ended ~~October~~April 3130, ~~2023~~2024, and ~~2022:~~2023.

	Three Months Ended				Nine Months Ended
	October 31,				October 31,
	2023		2022		2023		2022
The components of lease expense were as follows:
Operating lease cost	$	39,995	$	39,995	$	119,986	$	119,986
Short-term lease cost		-		-		36,715		-
Variable lease cost		12,186		6,202		31,925		18,603
Total lease cost	$	52,181	$	46,197	$	188,626	$	138,589

The components of lease expense were as follows:

F-12 Table of Contents

	Three Months Ended
	April 30,
	2024		2023
Operating lease cost	$	39,995	$	39,995
Short-term lease cost		-		14,788
Variable lease cost		10,108		9,197
Total lease cost	$	50,103	$	63,980

Supplementary information on cash flow and other information for leasing activities for the ~~nine~~three months ended ~~October~~April 3130, ~~2023~~2024, and ~~2022~~2023 are as follows:

	Nine Months Ended
	Three Months Ended
	October 31,
	April 30,
	2023			2022
	2024			2023
Cash paid for operating cash flows from operating leases	$	~~140~~48,~~365~~038		$	~~134~~46,~~940~~164
Right-of-use asset obtained in exchange for new operating lease liabilities	$	-		$	-
Remaining lease term - operating leases (year)		0.25			1.25
Remaining lease term - operating leases (year)		0.75			1.75
Discount rate — operating leases		10.00	%		10.00	%

~~Future~~Supplemental ~~minimum~~balance ~~lease~~sheet ~~payments~~information ~~under~~related ~~non-cancelable~~to leases asconsists of ~~October 31, 2023 are as follows~~:

Year ending January 31,
	April 30,			January 31,
2024 - remaining three months	$	48,038
	2024			2024
2025		96,075
Operating lease right-of-use asset	$	45,407		$	89,652
Thereafter		-
Operating lease liabilities:
		144,113
Current portion	$	47,248		$	93,334
Less: Imputed interest		(5,826	)
Non-current portion		-			-
Total	$	138,287
	$	47,248		$	93,334

The following table outlines the maturities of our lease liabilities as of April 30, 2024:

Year ending January 31,
2025 (excluding the three months ended April 30, 2024)	$	48,038
Thereafter		-
		48,038
Less: Imputed interest		(790	)
Total	$	47,248

F-13

Table of Contents

Note 7 – COMMITMENTS AND CONTINGENCIES

Legal Proceedings

The Company is from time to time involved in ~~ordinary~~ routine litigation incidental to the conduct of ~~its~~our business. ~~The~~Management ~~Company~~believes ~~regularly~~that ~~reviews~~no ~~all~~ pending litigation matters into which it is ~~involved~~a ~~and~~party ~~establishes~~is reserves deemed appropriate for such litigation matters, which reserved amounts are charged to operations in the year during which they are accrued. The Company believes that no presently pending litigation matters are likely to have a material adverse effect on the Company’s financial ~~statements~~condition or results of operations~~, taken as a whole~~.

~~During~~As ~~the~~previously ~~reporting~~disclosed ~~period,~~in ~~the~~our Company’s ~~became~~Form ~~aware~~10-K ~~that~~for ~~its~~the ~~former~~fiscal ~~Chief~~year ~~Executive~~ended ~~Officer~~January 31, ~~Mr. Cheng-Hsiang Kao~~2023, and ~~Chairman~~in ofour ~~the~~Report ~~Board,~~on ~~Mr.~~Form ~~Pao~~8-~~Chi~~K ~~Chu~~filed August 11, 2025, certain of our former officers are involved in civil and criminal ~~legal~~ proceedings in Taiwan. ~~The~~relating ~~proceedings~~to ~~involve~~alleged ~~allegations concerning the~~ unauthorized use ~~or disclosure~~ of ~~business~~proprietary know-how and intellectual property. The Company is not a named party into these proceedings. On August 7, 2025, Mr. Kao and Chu, along with the other officers resigned and appointed Ms. Ssu-Chuan Lai as the sole director and to all of the officer positions. The new management has evaluated the available information and, as of the balance sheet date, concluded that the matters are not expected to have a material adverse effect on the Company’s financial condition or results of operations. Management will continue to monitor the situation and assess any implications on the Company’s leadership or its operations.

~~Note~~As 8of –April ~~CONCENTRATION~~30, OF2024, ~~CREDIT~~and ~~RISK~~through the date of issuance of these financial statements, management is not aware of any developments that would cause the Company to conclude that these matters will have a material adverse effect on its financial condition or results of operations.

~~The~~Note ~~Company~~8 ~~did~~– ~~not~~SUBSEQUENT have any significant customer concentration during the three and nine months ended October 31, 2023. The Company did not have any significant customer concentration during the three months ended October 31, 2022. The Company had one customer that accounted for more than 10% of the Company’s total sales for the nine months ended October 31, 2022. The one customer represented $1,490,000 and 100% in aggregate of total sales for the nine months ended October 31, 2022.EVENTS

The Company ~~did~~has ~~not~~evaluated ~~have~~subsequent ~~any~~events ~~significant~~in ~~purchase~~accordance ~~concertation~~with Accounting ~~during~~Standards ~~the~~Codification ~~three~~(“ASC”) ~~and~~Topic ~~nine months ended October 31~~855, ~~2023.~~Subsequent ~~The Company did not have any significant purchase concertation during the three months ended October 31, 2023~~Events. ~~The~~Management ~~Company~~reviewed ~~had~~all ~~one~~events ~~vendor~~and transactions that ~~accounted~~occurred ~~for~~after ~~more than 10% of~~ the ~~Company’s~~balance ~~total~~sheet ~~purchases~~date ~~for the nine months ended October 31, 2022. The one vendor represented 100%~~ of ~~the Company’s total purchases for the three months ended~~ April 30, ~~2022.~~2024, Ifthrough the ~~Company~~date ~~lost this one vendor, this could have a negative impact upon~~ the financial ~~well-being~~statements ofwere ~~the Company~~issued.

~~Note~~F-14 9Table –of ~~SUBSEQUENT EVENTS~~Contents

The Company has evaluated subsequent events in accordance with Accounting Standards Codification (“ASC”) Topic 855, Subsequent Events. Management reviewed all events and transactions that occurred after the balance sheet date of October 31, 2023, through the date the financial statements were issued.

F-13 Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our unaudited financial statements, ~~including~~and the related notes ~~thereto,~~included ~~appearing elsewhere~~ in this Quarterly Report on Form 10-Q. ~~This~~The ~~section~~discussion below contains forward-looking statements that involve risks and uncertainties~~, and reflect our plans, estimates and beliefs~~. Our actual results ~~could~~may differ materially from those ~~discussed~~anticipated ~~below.~~in ~~See~~these ~~“Special~~forward-looking ~~Note~~statements ~~Regarding~~due ~~Forward-Looking~~to ~~Statements.~~various factors, including those described in our filings with the Securities and Exchange Commission (“SEC”).

Forward-Looking Statements

This ~~annual~~quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. These statements often can be identified by the use of terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “approximate” or “continue,” or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management’s best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

AsUnless ~~used~~otherwise ~~in this annual report~~indicated, ~~the~~references ~~terms~~to “we,” “us,” “our,” or “the Company,” mean VitaSpring Biomedical Co., Ltd.~~, unless otherwise indicated.~~

All dollar amounts refer to US dollars unless otherwise indicated.

Overview

We are a development-stage biomedical ~~and nutraceutical~~ company focused on cell-based technologies for regenerative and preventative health applications. ~~engaged~~Our inbusiness ~~the~~model ~~research,~~historically ~~development,~~involved ~~and~~sourcing ~~commercialization~~stem ofcells ~~products that promote wellness~~ and aexosome ~~healthy~~products ~~lifestyle.~~from ~~We began limited operations in 2019 and underwent~~ a ~~change~~related-party ofvendor ~~ownership effective January 21, 2020, resulting in a new management team~~ and ~~strategic~~reselling ~~direction.~~those Inproducts ~~connection with this ownership change, we filed a Certificate of Amendment~~ to ~~our Articles of Incorporation to change our corporate name to VitaSpring Biomedical Co~~customers. ~~Ltd., which became effective on April 21, 2020, following clearance by the Financial Industry Regulatory Authority (“FINRA”).~~

AsDuring of the ~~date~~three ofmonths ~~this~~ended ~~filing~~April 30, 2024, and 2023, we ~~have~~did not ~~commenced~~generate ~~principal~~any revenue~~-generating~~ ~~operations~~as ~~and~~we ~~have~~restructured ~~generated~~our ~~limited~~commercial ~~revenues~~strategy, ~~since~~evaluated ~~inception.~~supplier ~~Our~~and ~~operations~~regulatory ~~have been limited to organizational activities~~considerations, ~~administrative functions,~~ and ~~preparation~~assessed ~~for~~ future ~~service~~business ~~offerings~~direction.

Accordingly, our activities during the current fiscal year have primarily consisted of:

	·	Administrative and corporate compliance activities,
	·	Evaluation of future commercialization strategy,
	·	Maintenance of regulatory positioning,
	·	Management of related party obligations, and
	·	Seeking additional capital to support future operations.

As of April 30, 2024, we have not reinitiated revenue-generating operations.

Results of Operation

~~For~~The ~~the~~following ~~three~~summary ~~months~~of ~~ended~~our ~~October~~results ~~31,~~of ~~2023~~operations should be read in conjunction with our ~~compared~~unaudited tofinancial ~~the~~statements ~~three~~for ~~months~~the period ended ~~October~~April 3130, ~~2022~~2024, which are included herein.

	Three months ended
	October 31,
	2023			2022			Changes
Revenues	$	-		$	-		$	-
Cost of goods sold		-			-			-
Operating expenses		234,980			183,219			51,761
Loss from operations		(234,980	)		(183,219	)		(51,761	)
Other expense		-			(637	)		637
Provision for income tax benefit		-			(45,575	)		45,575
Net loss	$	(234,980	)	$	(138,281	)	$	(96,699	)

Table of Contents

Our operating results for the three months ended April 30, 2024, and 2023 and the changes between those periods for the respective items are summarized as follows.

For the three months ended April 30, 2024, compared to the three months ended April 30, 2023

	Three Months ended
	April 30,
	2024			2023			Changes
Revenues	$	-		$	-		$	-
Operating expenses		216,831			304,601			(87,770	)
Loss from operations		(216,831	)		(304,601	)		87,770
Net loss	$	(216,831	)	$	(304,601	)	$	87,770

Revenue

WeDuring ~~generated no revenue during~~ the three months ended ~~October~~April 3130, 2024, and 2023, we did not generate any revenue. During the year 2023, we suspended commercial sales activity while evaluating our operating model and ~~2022~~funding alternatives. We are currently focusing on restructuring our product strategy and developing long-term partnerships rather than pursuing short-term sales.

~~Cost~~We had a net loss from operations of ~~Goods~~$216,831 ~~Sold~~for the three months ended April 30, 2024, and $304,601 for the three months ended April 30, 2023. The decrease in net loss of $87,770 was due to a reduction in operating expenses of $87,770.

We did not generate any cost of goods sold due to no revenue in the three months ended October 31, 2023 and 2022.

Operating Expenses

~~Operating~~The operating expenses ~~totaled~~for ~~$234,980 in~~ the three months ended ~~October~~April 3130, 2024, and 2023 ~~compared~~were ~~with~~$216,831 and $~~183~~304,~~219~~601, inrespectively. For the three months ended ~~October~~April 3130, ~~2022.~~2024, ~~The~~and ~~increase~~2023, inthe operating ~~expense~~expenses iswere ~~mainly~~primarily ~~due~~attributed to anprofessional ~~increase~~fees inof ~~professional~~$32,026 ~~fees.~~and We$76,173, ~~continue~~stock-based tocompensation ~~carefully~~of ~~manage~~$41,217 ~~overhead~~and ~~while~~$41,216, ~~maintaining~~lease ~~core~~expenses ~~research~~of $50,103 and ~~corporate~~$63,980, ~~functions~~depreciation expenses of $2,489 and $3,766, payroll expenses of $84,578 and 41,118 and general and administrative expenses of $6,418 and $78,348, respectively.

Other Income (expense)

We recorded no other income in the three months ended October 31, 2023 compared with other expense of $637, which primarily represents miscellaneous non-operating income in the three months ended October 31, 2022.

Provision for Income Taxes

Our income tax expense was $0 in three months ended October 31, 2023, compared with a tax benefit of $45,575 in the three months ended October 31, 2022. The variance primarily reflects the change from profitability in 2022 to a loss in 2023 and adjustments to deferred tax items.

Net Loss

AsFor athree ~~result~~months ofended ~~the~~April ~~foregoing~~30, 2024, and 2023, we ~~recorded~~had a net loss of $~~234~~216,~~980~~831 and $ 304,601, respectively. Net loss decreased by $87,770, or 28.81%, to $216,831 for the three months ended ~~October~~April 3130, ~~2023~~2024, compared with net loss of $~~138~~304,~~281~~601 in the three months ended ~~October~~April 3130, ~~2022~~2023. The ~~increase~~decrease in net loss was ~~mainly~~ due to ~~the~~decrease ~~continuation~~in ~~of fixed~~ operating ~~costs~~expenses.

~~For~~Balance ~~the~~Sheet ~~nine months ended October 31, 2023 compared to the nine months ended October 31, 2022~~Data

	Nine months ended
	October 31,
	2023			2022			Changes
Revenues	$	-		$	1,490,000		$	(1,490,000	)
Cost of goods sold		-			922,000			(922,000	)
Operating expenses		893,164			582,603			310,561
Income (loss) from operations		(893,164	)		(14,603	)		(878,561	)
Other income		-			7,935			(7,935	)
Provision for income taxes		-			(908	)		908
Net income (loss)	$	(893,164	)	$	(5,760	)	$	(887,404	)

Revenue

We generated no revenue during the nine months ended October 31, 2023, compared with $1,490,000 in the nine months ended October 31, 2022. The decrease was due to the no product sales in the nine months ended October 31, 2023. We are currently focusing on restructuring our product strategy and developing long-term partnerships rather than pursuing short-term sales.

5 Table of Contents

Cost of Goods Sold

Cost of goods sold was $0 in the nine months ended October 31, 2023 compared with $922,000 in the nine months ended October 31, 2022. We did not generate any cost of goods sold due to no revenue in the three months ended October 31, 2023.

Operating Expenses

Operating expenses totaled $893,164 in the nine months ended October 31, 2023 compared with $582,603 in the nine months ended October 31, 2022. The increase in operating expense is mainly due to the opening of Taiwan office to seek business. We continue to carefully manage overhead while maintaining core research and corporate functions.

Other Income

We recorded no other income in the nine months ended October 31, 2023 compared with $7,935, which primarily represents miscellaneous non-operating income in the nine months ended October 31, 2022.

Provision for Income Taxes

Our income tax expense was $0 in fiscal 2023, compared with a tax benefit of $908 in the nine months ended October 31, 2022. The variance primarily reflects the change from profitability in 2022 to a loss in 2023 and adjustments to deferred tax items.

Net Loss

As a result of the foregoing, we recorded a net loss of $893,164 for the nine months ended October 31, 2023, compared with net loss of $5,760 in the nine months ended October 31, 2022. The increase in net loss was mainly due to the absence of revenue and the continuation of fixed operating costs.

Liquidity and Capital Resources

The following table summarizes our changes in working capital deficiency from ~~January~~April 3130, ~~2023~~2024, to ~~October~~January 31, ~~2023~~2024:

	October 31,			January 31,
	April 30,			January 31,
	2023			2023			Change
	2024			2024			Change
Current assets	$	~~106~~64,~~308~~307		$	~~437~~23,~~078~~627		$	~~(330~~40,~~770~~680	)
Current liabilities	$	3,~~443~~657,~~357~~091		$	3,~~069~~487,~~106~~531		$	~~374~~169,~~251~~560
Working capital (deficiency)	$	(3,~~337~~592,~~049~~784	)	$	(23,~~632~~463,~~028~~904	)	$	(~~705~~128,~~021~~880	)

~~The~~As ~~following~~of ~~table~~April ~~summarizes~~30, 2024, our ~~cash~~current ~~flows~~assets ~~for~~were ~~the~~$64,307 ~~nine~~and ~~months~~our ~~ended~~current ~~October~~liabilities were $3,657,091, which resulted in working capital deficiency of $3,592,784. As of April 30, 2024, and January 31,2024, ~~2023~~current assets were comprised of $968 and ~~2022:~~$13 in cash, $39,725 and $0 in prepaid expenses and $23,614 and $23,614 in deposits, respectively.

	Nine months ended
	October 31,
	2023			2022			Change
Cash (used in) operating activities	$	(32,297	)	$	(83,162	)	$	50,865
Cash provided by financing activity	$	5,277		$	-		$	5,277
Net change in cash	$	(27,020	)	$	(83,162	)	$	56,142

Table of Contents

As of ~~October~~April 3130, ~~2023~~2024, weand ~~had~~January ~~cash~~31,2024, ~~approximately~~current liabilities were comprised of $3 2,411,000 and $2,411,000 ~~compared~~in ~~with~~accounts ~~cash~~payable of-related party, $30279,~~000~~056 atand ~~January~~$339,001 31in accounts payable and other payables, ~~2023.~~$218,714 ~~The~~and ~~decrease~~$218,714 ofin ~~approximately~~income tax payable, $2747,~~000~~248 ~~was~~and ~~mainly~~$93,334 ~~due~~in tooperating ~~cash~~lease ~~used~~liabilities and $701,073 and $425,482 in ~~our~~advances ~~operations~~from related party, respectively.

6Our ~~Table~~working capital deficiency increased by $128,880, or 3.72%, to $3,592,784 for the three months ended April 30, 2024, compared to working capital deficiency of ~~Contents~~$3,463,904 as of January 31, 2024. The increase was primarily due to an increase in advances from related party offset by a decrease in accounts payable, operating lease liabilities and an increase in current assets.

WeThe ~~have~~income ~~funded~~tax ~~our~~payable ~~activities~~balance primarily ~~through~~relates ~~shareholder~~to ~~advances.~~historical Wetax ~~incurred a net loss of $893~~liabilities,~~164~~ inand ~~the~~no ~~nine~~current ~~months~~period ~~ended~~income ~~October~~tax ~~31,~~expense ~~2023.~~was Werecorded ~~continue~~due to ~~rely on external funding and available cash balances to meet~~ our ~~working-capital~~net ~~needs.~~operating ~~Management~~loss ~~believes~~position ~~that~~and ~~additional~~full ~~capital~~valuation ~~will be required to support operations over the next twelve months~~allowance.

Cash Flow Data

The following table summarizes our cash flows for the three months ended April 30, 2024, and 2023:

	Three Months ended
	April 30,
	2024			2023			Change
Cash used in operating activities	$	(4,023	)	$	(27,940	)	$	23,917
Cash provided by financing activity	$	4,978		$	1,277		$	3,701
Net change in cash	$	955		$	(26,663	)	$	27,618

As of April 30, 2024, we had cash of $968, compared with cash of $13 at January 31, 2024. The increase of approximately $955 was mainly due to cash provided in our financing activities.

We have funded our activities primarily through shareholder advances, which were discretionary and not subject to a written agreement. For the three months ended April 30, 2024, we incurred a net loss of $216,831. We continue to rely on external funding and available cash balances to meet our working-capital needs. Management believes that additional capital will be required to support operations over the next twelve months.

We expect to continue to require additional capital to support operations, research, and regulatory initiatives. Management is exploring potential sources of financing, including private placements of equity or debt securities and strategic partnerships. There is no assurance that additional funding will be available on acceptable terms. If we cannot secure sufficient financing, we may need to delay or scale back parts of our business plan.

We believe our current cash resources will not be sufficient to fund planned operations for the next twelve months without additional capital. The continuation of our business depends on our ability to raise funds and generate future revenue.

~~Operating~~Historically, ~~Activities~~substantially all of our product inventory was sourced from a single, related-party vendor.

Cash ~~used~~Flows infrom ~~operating~~Operating activities of $32,297 for the nine months ended October 31, 2023 reflected primarily our net loss of $893,164 increased by depreciation of $11,297, non-cash lease expense of $122,918 and stock-based compensation of $1263,648, and a change in assets and liabilities of $603,004.Activities

~~Cash~~We have not generated positive cash flows from operating activities. Net cash used in operating activities ofwas $834,~~162~~023 for the ~~nine~~three months ended ~~October~~April 3130, ~~2022~~2024, ~~reflected~~which primarily reflects our net loss of $5216,~~760~~831, ~~increased~~adjusted for non-cash items and charges in working capital reduced by depreciation of $112,~~297~~489, non-cash lease expense of $~~137~~44,~~554~~245, stock-based compensation of $~~109~~41,~~527~~217, ~~and~~advances ~~deferred~~from ~~tax~~related ~~benefit~~party for operating expenses of $1270,~~708~~613, and increased by a net change in ~~assets~~working ~~and~~capital ~~liabilities~~ of $~~334~~145,~~072~~756.

~~Investing~~Net ~~Activities~~cash used in operating activities was $27,940 for the three months ended April 30, 2023, primarily due to our net loss of $304,601, reduced by depreciation of $3,766, non-cash lease expense of $39,953, stock-based compensation of $41,216, accounts receivable of $150,000, advances from related party for operating expenses of $51,594 and increased by a net change in working capital of $9,868.The accounts receivable collected during the period related primarily to revenue recognized in 2022.

We6 ~~had~~Table noof ~~investing activities during the nine months ended October 31, 2023 and 2022.~~Contents

~~Financing~~Cash ~~Activity~~Flows from Investing Activities

We ~~has financing inflow of $5,277 from advances from related parties in the nine months ended October 31, 2023. We~~ had no ~~financing~~investing ~~inflows~~activities induring the ~~nine~~three months ended ~~October~~April 3130, ~~2022.~~2024, Weand ~~may seek additional equity or debt financing in future periods to support ongoing operations~~2023.

Cash Flows from Financing Activities

Net cash provided by financing activities was $4,978 for the three months ended April 30, 2024, compared to $1,277 for the three months ended April 30, 2023.

During the three months ended April 30, 2024, and 2023, the Company received advances from a related party of $4,978 and $1,277, respectively. We may seek additional equity or debt financing in future periods to support ongoing operations.

We expect to continue to rely on equity financing and, where available, strategic partnerships or grants to meet our capital needs. Our ability to raise additional capital will depend on market conditions, investor interest, and our progress in commercializing our stem-cell and biomedical technologies.

Capital Requirements and Liquidity Outlook

We have incurred losses and negative cash flow from operations. We believe that our ~~existing~~current cash resources ~~will~~are not be sufficient to fund our operations for the next twelve months without additional financing. To meet our capital needs, we plan to seek additional equity or debt financing and may also pursue strategic partnerships or licensing opportunities. There is no assurance that such financing will be available on favorable terms or at all. If we cannot obtain adequate funding, we may need to delay, scale back, or discontinue some of our business activities.

Going Concern

We evaluate our ability to continue as a going concern in accordance with ASC 205-40, Presentation of Financial Statements — Going Concern. This evaluation requires us to assess whether conditions or events raise substantial doubt about our ability to meet our obligations as they become due during the twelve months following the issuance of these financial statements.

Our financial statements have been prepared assuming we will continue as a going concern. As disclosed in Note 2 to our financial statements, as of ~~October~~April 3130, ~~2023~~2024, we had an accumulated deficit of $4,~~281~~723,~~183~~412, a working capital deficiency of $3,592,784, and negative operating cash flow of $324,~~297~~023, ~~and~~which is due to our limited operations,. ~~which~~These factors raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these financial statements. Our ~~continued~~ability ~~existence~~to iscontinue ~~dependent~~as a going concern depends upon our ability to obtain additional funding, restructuring related-party obligations, and implement a business plan that generates sustainable revenues. There can be no assurance that we will be successful in these efforts.

7 Table of Contents

Off-Balance Sheet Arrangements

As of ~~the~~April ~~date~~30, ~~of this Quarterly Report~~2024, we dodid not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business.

~~Existing~~While existing working capital, ~~further~~together ~~advances~~with ~~and~~anticipated ~~debt instruments~~financing, ~~and~~is ~~anticipated cash flow are~~ expected to be adequate to fund our operations over the next twelve months, there can be no assurances that it will be adequate. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

Table of Contents

Critical Accounting Policies and Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosures. The Company’s significant accounting policies are described in Note 4 to the financial statements. Management considers the following policies to be critical because they involve significant judgments and assumptions, and because different assumptions could materially affect the Company’s financial condition or results of operations. Critical estimates are those estimates that in accordance with U.S. GAAP, involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial statements. Management has determined that our most critical accounting estimates are those relating to fair value of financial instruments.

Use of Estimates

~~The~~Our ~~preparation of~~ financial statements are prepared in ~~conformity~~accordance with ~~U.S.~~accounting principles generally accepted ~~accounting~~in ~~principles~~the United States of America (“U.S. GAAP”). ~~ordinarily~~The preparation of financial statements requires management to make estimates and assumptions, ~~that~~including, ~~affect~~but ~~the~~not ~~reported~~limited ~~amounts~~to, ofstock-based ~~assets~~compensation, lease liabilities, ~~revenues,~~ and ~~expenses~~going concern assessment. ~~However,~~Our ~~for~~significant accounting policies are described in Note 4 to the ~~quarter~~financial ~~ended~~statements. ~~October~~We ~~31,~~consider ~~2023,~~the ~~our~~following ~~operations~~policies and ~~financial~~estimates ~~statement~~to ~~items~~be ~~did~~critical ~~not~~because ~~require~~they ~~the~~involve ~~use~~significant judgments and assumptions and could materially affect our financial condition and results of ~~any~~operations. ~~significant~~Critical estimates are those estimates orthat ~~assumptions~~in accordance with U.S. ~~All~~GAAP, ~~amounts~~involve ~~presented~~a significant level of estimation uncertainty and have had or are ~~based~~reasonably likely to have a material impact on ~~actual,~~our ~~readily~~financial ~~determinable~~statements. ~~values,~~Management ~~and~~has nodetermined ~~material~~that ~~judgments~~our ormost ~~estimation~~critical ~~methodologies~~accounting ~~were~~estimates ~~applied~~are those relating to fair value of financial instruments.

~~Fair~~Significant ~~Value~~estimates ofand ~~Financial~~assumptions ~~Instruments~~reflected in the financial statements for the quarter ended April 30, 2024, include, but are not limited to:

~~The~~Allowance Company follows ASU 2022-03, ASC Subtopic “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions” (“ASC 820”), which defines fair value as the exchange price that would be received for anCredit asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:Losses

~~Level~~We 1evaluate financial assets measured at amortized cost, including accounts receivable, for expected credit losses under ASC 326. The estimate incorporates historical loss experience, current economic conditions, and reasonable and supportable forecasts. Changes in these factors could materially affect the allowance recorded.

~~Level~~Lease ~~1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.~~Accounting

Under ASC 842, we recognize right-of-use assets and lease liabilities for operating leases. When the implicit rate in a lease is not readily determinable, we estimate an incremental borrowing rate based on available market information and our credit profile. Changes in assumptions regarding discount rates could impact lease liabilities and related expense.

Deferred Tax Assets

We recognize deferred tax assets and liabilities for temporary differences between financial statement carrying amounts and tax bases. We evaluate the realizability of deferred tax assets and record a valuation allowance when it is more likely than not that some or all of the deferred tax assets will not be realized. This assessment requires significant judgment regarding future taxable income.

Stock-Based Compensation

We account for equity-based awards under ASC 718. The fair value of equity awards is measured at the grant date and recognized over the requisite service period. The determination of fair value may require management to make assumptions regarding expected term, volatility, and other valuation inputs, as applicable.

Going Concern Assessment

In accordance with ASC 205-40, we evaluate whether conditions or events raise substantial doubt about our ability to continue as a going concern within one year from the issuance date of the financial statements. This assessment requires management to evaluate liquidity, forecasted cash flows, and the availability of financing or related-party support.

Because these estimates require management judgment, actual results could differ materially from those estimates.

Table of Contents

Level 2

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The carrying amounts shown of the Company’s financial instruments including cash and cash equivalents and accounts payable approximate fair value due to the short-term maturities of these instruments.

Income Taxes and Deferred Tax Assets

We account for income taxes using the liability method under ASC 740. Deferred tax assets are recognized for temporary differences between financial statement and tax bases of assets and liabilities. A valuation allowance is established when it is more likely than not that all or part of a deferred tax asset will not be realized. Determining the amount of valuation allowance requires significant judgment in estimating future taxable income, applicable tax strategies, and the expected timing of reversals of temporary differences.

Material Commitments

None.

Purchase of Significant Equipment

We do not intend to purchase any significant equipment during the next twelve months.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company and not required to provide this information.

Table of Contents

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (CEO), is responsible for establishing and maintaining disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”). Disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including the CEO, to allow timely decisions regarding required disclosure.

As of the end of the fiscal quarter ended ~~October~~April 3130, ~~2023~~2024, management conducted an evaluation, under the supervision and with the participation of our CEO, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our CEO concluded that our disclosure controls and procedures were not effective as of ~~October~~April 3130, ~~2023~~2024, due to a material weakness in our internal control over financial reporting, as described below.

9 Table of Contents

Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, evaluations of effectiveness to future periods are subject to the risk that controls may become inadequate due to changes in conditions or deterioration in compliance with policies or procedures.

Management assessed the effectiveness of our internal control over financial reporting as of ~~October~~April 3130, ~~2023~~2024, using the criteria set forth in the Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this assessment, management concluded that our internal control over financial reporting was not effective as of that date, due to the following material weakness:

Material Weakness Identified: We did not maintain an adequate segregation of duties or employ sufficient accounting personnel with appropriate experience in U.S. GAAP and SEC reporting requirements. This deficiency increased the risk of material misstatements in the financial reporting process.

Remediation Plan

We are committed to ~~improving~~strengthening our internal control ~~environment.~~over Tofinancial ~~remediate~~reporting and remediating the identified material weakness, werelated ~~plan~~ to ~~evaluate~~insufficient ~~and~~accounting ~~enhance our internal control procedures and, as resources permit, hire additional qualified~~ personnel ~~or engage external consultants with relevant expertise in financial reporting~~ and ~~SEC~~lack ~~compliance.~~of Wesegregation ~~intend to enhance our internal control procedures in Q1~~ of ~~2026~~duties.

~~Changes~~We inintend ~~Internal~~to ~~Control~~adopt ~~Over~~the ~~Financial~~following ~~Reporting~~remediation plan subject to funding and retaining the appropriate personnel:

~~There~~1. ~~were~~Engagement noof ~~changes~~External inAccounting our internal control over financial reporting during the fiscal quarter ended October 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.Support

We intend to engage an independent accounting consultant with SEC reporting experience no later than September 30, 2026. The consultant will assist management with:

	·	Review of quarterly and annual financial statements,

	·	Technical accounting research and documentation,

	·	Preparation and review of SEC filings,

	·	Implementation of formalized closing procedures and documentation standards.

Table of Contents

2.	Implementation of Formalized Closing and Review Controls

Beginning with the quarter ending September 30, 2026, we intend to implement enhanced month-end and quarter-end closing procedures, including:

	·	Standardized account reconciliation templates,

	·	Documented supervisory review controls,

	·	Checklist-driven SEC filing review procedures,

	·	Formal review and approval of journal entries.

3.	Segregation of Duties Enhancement

By January 31, 2027, we intend to establish improved segregation of duties through a combination of:

	·	Clearly documented role assignments,

	·	Independent review of financial reporting by the external consultant or qualified third party,

	·	Enhanced board-level oversight of financial reporting processes.

4.	Ongoing Monitoring and Documentation

We will document the design and implementation of revised controls and evaluate their operating effectiveness over a sufficient period of time prior to concluding that the material weakness has been remediated.

The remediation efforts described above are dependent on our ability to secure adequate financial resources. We do not make any assurances that we will be able to secure the necessary resources to implement the foregoing plan. We expect to substantially complete implementation of these remediation measures by January 31, 2027. However, the material weakness will not be considered remediated until the applicable controls have been designed, implemented, and tested for operating effectiveness over a sustained period.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the fiscal quarter ended April 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

WeThe ~~are~~Company ~~not~~is ~~subject~~from time to ~~any~~time ~~legal~~involved ~~proceedings~~in ~~and~~routine ~~are~~litigation ~~unaware~~incidental to the conduct of ~~any~~our business. Management believes that no pending ~~against~~litigation usmatters to which it is a party is likely to have a material adverse effect on the Company’s financial condition or results of operations.

As previously disclosed in our ~~Current~~Company’s ~~Report on~~ Form 810-K ~~filed~~for ~~with~~ the ~~Securities~~fiscal year ended January 31, 2023, and ~~Exchange~~in ~~Commission~~our Report on Form 8-K filed August 11, 2025, certain of our former officers ~~and~~are ~~our~~involved ~~director~~in ~~are~~civil ~~subject~~and ofcriminal ~~legal~~ proceedings in Taiwan. ~~These~~relating ~~matters~~to doalleged ~~not~~unauthorized ~~involve~~use ~~us,~~of ~~and~~proprietary weknow-how ~~are~~and ~~not~~intellectual aproperty. ~~party~~The toCompany ~~any~~is ofnot ~~the~~a ~~proceedings~~named ~~referenced~~party into ~~the~~these ~~Form 8-K~~proceedings.

~~Please~~As ~~refer~~of toApril 30, 2024, and through the ~~Form~~date ~~8-K~~of ~~for~~issuance ~~additional~~of ~~information~~these ~~regarding~~financial ~~those~~statements, management is not aware of any developments that would cause the Company to conclude that these matters will have a material adverse effect on its financial condition or results of operations.

Item 1A. Risk Factors

WeRISKS ~~are~~RELATED aTO ~~smaller~~OUR ~~reporting~~FINANCIAL ~~company~~CONDITION, ~~and~~LIQUIDITY ~~not~~AND ~~required~~GOING ~~to provide this information.~~CONCERN

Substantial doubt exists regarding our ability to continue as a going concern.

We have not generated revenue during the three months ended April 30, 2024. As of April 30, 2024, we had cash of $968, total assets of $64,307, total liabilities of $3,657,091, an accumulated deficit of $4,723,412, and a stockholders’ deficit of $3,525,803. We have incurred recurring losses since inception and expect to continue incurring losses for the foreseeable future. Based on our current cash position and expected expenditure, we do not have sufficient liquidity to fund operations for the next twelve months without additional financing.

Our financial statements have been prepared assuming we will continue as a going concern. Management has concluded that substantial doubt exists regarding our ability to continue as a going concern within twelve months from the issuance of our financial statements. Our independent registered public accounting firm has included a going concern explanatory paragraph in prior audit reports.

Based on our current cash position and expected operating expenditure, we do not have sufficient liquidity to fund operations for the next twelve months without additional financing. We do not have written agreements with related parties that contractually defer repayment of these obligations.

We have no committed financing arrangements and no revenue-generating operations. Our ability to continue operations depends entirely upon raising additional capital or obtaining continued financial support from related parties. There can be no assurance that such capital will be available on acceptable terms, if at all. If we are unable to secure adequate funding, we may be forced to significantly curtail or cease operations, seek protection under applicable insolvency laws, or liquidate our assets.

Our liabilities substantially exceed our assets, which may impair our ability to obtain financing and satisfy uplisting requirements.

Our negative stockholders’ equity position may adversely affect investor confidence and impair our ability to obtain financing on favorable terms. Certain trading platforms and exchanges impose minimum stockholders’ equity requirements. Our current financial condition may limit our ability to satisfy such requirements, thereby restricting our ability to uplist our common stock to OTCQB or a national securities exchange. Certain markets, including the OTCQB and the national securities exchanges, require minimum stockholders’ equity thresholds that we currently do not meet.

We may not be able to satisfy our obligations as they become due.

A substantial portion of our liabilities consists of unsecured obligations to related parties and vendors. These obligations may be payable on demand. If creditors demand repayment or decline to extend payment terms, we may be unable to satisfy such obligations when due, which could result in default, litigation, or insolvency proceedings. To date, no formal demand for repayment has been made.

Table of Contents

RISKS RELATED TO OUR DEVELOPMENT-STAGE STATUS AND BUSINESS STRATEGY

We have not commenced commercial operations and have no history of revenue generation.

Although we describe a long-term strategy involving regenerative medicine technologies, including potential stem-cell and exosome-based applications, we have not commenced commercial manufacturing, distribution, or revenue-generating activities. We did not incur research and development expenses in current period ended April 30,2024 or fiscal year ended January 31, 2024, have not initiated clinical trials, and have not obtained regulatory approvals. Our limited operating history makes it difficult for investors to evaluate our prospects. As of the date of this Quarterly Report, we are not actively developing, manufacturing, or marketing any products.

Our business model is speculative and subject to significant execution risk.

	·	Our future success depends on numerous factors, including:

	·	Securing sufficient capital;

	·	Recruiting qualified personnel;

	·	Obtaining regulatory approvals;

	·	Protecting intellectual property;

	·	Establishing manufacturing capabilities;

	·	Entering into strategic partnerships;

	·	Achieving market acceptance.

Each of these elements involves significant uncertainty. Failure in any of these areas could materially adversely affect our business.

We may change our business strategy.

Given our financial condition and development-stage status, we may revise or modify our business strategy. Such changes may expose us to additional risks and uncertainties and may not result in successful operations.

RISKS RELATED TO REGULATORY MATTERS

If we pursue regenerative medicine or biologic-based products, we will be subject to extensive regulatory requirements.

Any future commercialization efforts may subject us to regulation by the U.S. Food and Drug Administration and comparable foreign regulatory authorities. Regulatory approval processes require extensive preclinical and clinical data and may take years to complete. Regulatory authorities may impose additional requirements, delay approvals, or deny approval altogether. We have not yet established FDA-compliant manufacturing facilities or submitted any investigational or marketing applications.

Failure to obtain or maintain regulatory approvals would prevent commercialization.

Even if approvals are obtained, regulatory authorities may impose post-marketing requirements, restrict indications, suspend approvals, or withdraw approval. Regulatory compliance requires substantial financial and managerial resources.

The regulatory landscape for stem-cell and exosome technologies is evolving.

Regulatory authorities have increased scrutiny of regenerative medicine therapies. Changes in regulatory policy, interpretation, or enforcement priorities may adversely affect our ability to develop or commercialize products.

Table of Contents

RISKS RELATED TO INTELLECTUAL PROPERTY

We do not currently hold issued patents.

As of the date of this report, we do not own issued patents, nor do we have any pending patent applications. We also do not own any registered trademarks. Our competitive position relies primarily on trade secrets and proprietary know-how. Trade secrets are difficult to protect, and we may not be able to prevent unauthorized disclosure or use.

We may become involved in intellectual property disputes.

If we develop technologies in the future, we may face claims of infringement from third parties. Defending against such claims could be costly and time-consuming. We may be required to pay damages, enter into licensing agreements on unfavorable terms, or cease certain operations.

RISKS RELATED TO RELATED-PARTY TRANSACTIONS AND CONFLICTS OF INTEREST

We have significant obligations to related parties, including a former officer who is involved in criminal proceedings unrelated to us.

As of April 30, 2024, we owed $2,411,000 to a related-party vendor, which is owned by our former officer, and $701,073 in advances from related parties, including advances made by a former Chief Executive Officer and Chairman of the Board. These obligations are unsecured, and are not subject to formal long-term repayment schedules, and may be payable on demand. The continuation of related-party financial support is not assured.

The former officer referenced above is involved in criminal proceedings relating to the alleged unauthorized use of intellectual property that was not owned by us and did not arise from our operations. We are not a party to these proceedings, and the allegations do not involve our assets, intellectual property, or current management. Nevertheless, because this individual is a creditor of us, developments in such proceedings could affect repayment discussions, restructuring negotiations, or future financing arrangements. In addition, public association with former management may result in reputational harm or investor concern.

If related parties demand repayment of outstanding amounts or cease providing financial support, our liquidity and ability to continue operations could be materially adversely affected.

Our governance structure may increase conflict-of-interest risk.

We currently have a single director who also serves as our sole executive officer. We do not have independent directors or standing committees. We have not adopted a formal related-party transaction policy. This structure may increase the risk of conflicts of interest and reduce oversight of management decisions.

RISKS RELATED TO FORMER MANAGEMENT AND LEGAL PROCEEDINGS

Former officers are involved in civil and criminal proceedings that could indirectly affect us.

Certain former officers and directors are involved in legal proceedings in Taiwan relating to alleged unauthorized use of intellectual property. Although we are not a named party, these proceedings may result in reputational harm, disruption of business relationships, or derivative claims.

We may be subject to litigation.

We may become involved in disputes related to intellectual property, contracts, securities laws, or other matters. Litigation is inherently uncertain and may result in substantial costs, diversion of management resources, or adverse judgments.

RISKS RELATED TO INTERNAL CONTROL OVER FINANCIAL REPORTING

We have identified a material weakness in internal control over financial reporting.

Management concluded that our internal control over financial reporting was not effective as of April 30, 2024, due to insufficient segregation of duties and lack of personnel with appropriate U.S. GAAP and SEC reporting expertise. If we fail to remediate this material weakness, we may be unable to prevent or detect material misstatements in our financial statements.

If we fail to remediate this material weakness, we may be unable to timely file reports with the SEC, which could result in loss of quotation eligibility or trading market restrictions.

Table of Contents

RISKS RELATED TO CAPITAL RAISING AND DILUTION

We will require substantial additional capital to execute our business strategy.

We anticipate funding operations through equity offerings, convertible securities, strategic partnerships, or related-party financing. Such financings may be highly dilutive and may include terms unfavorable to existing stockholders. Our net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code.

Future issuances of securities may dilute existing stockholders and depress our stock price.

We may issue additional shares of common stock or securities convertible into common stock at prices below current market value. Such issuances may include warrants, anti-dilution adjustments, or other terms that adversely affect existing stockholders.

Our net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code, which could reduce or eliminate their value.

As of April 30, 2024, we had federal net operating loss (“NOL”) carryforwards. Our ability to utilize these NOLs to offset future taxable income, if any, may be significantly limited under Section 382 of the Internal Revenue Code of 1986, as amended (“Section 382”), if we experience an “ownership change” as defined in Section 382.

In general, an ownership change occurs if the percentage of our stock owned by one or more “5-percent shareholders” increases by more than 50 percentage points over a rolling three-year testing period. Because our stock ownership is relatively concentrated and because we may issue additional equity or convertible securities in future financings, we may experience an ownership change under Section 382. An ownership change could materially limit the amount of NOLs that may be utilized annually to offset taxable income. In certain circumstances, such limitations could effectively eliminate the benefit of our NOL carryforwards.

In addition, if we undergo a significant change in business operations or experience future ownership changes, our ability to utilize our NOLs could be further limited. Any such limitation could reduce the potential tax benefits available to us and may adversely affect our financial condition and results of operations.

There can be no assurance that our NOL carryforwards will be available to offset future taxable income, even if we achieve profitability.

RISKS RELATED TO UPLISTING AND MARKET STATUS

Because we currently have a stockholders’ deficit and lack independent directors, we may not satisfy the financial and governance requirements necessary to uplist to OTCQB or a national securities exchange.

We are contemplating an uplisting our common stock. Uplisting requires compliance with financial, corporate governance, and market-based criteria, including minimum bid price, stockholders’ equity thresholds, and independent board requirements. Our current financial condition and governance structure may prevent us from meeting such criteria. We may need to effect a reverse stock split to meet minimum bid price requirements, which could adversely affect stockholder value.

Our common stock is thinly traded and may experience significant volatility.

Our common stock trades on the OTC Pink marketplace, which generally has lower liquidity and greater volatility than national securities exchanges. Limited trading volume may result in substantial price fluctuations.

Our common stock may be subject to penny stock regulations.

If our common stock is deemed a penny stock, broker-dealers may be subject to additional regulatory requirements before effecting transactions, which may reduce liquidity and investor interest.

Table of Contents

RISKS RELATED TO CYBERSECURITY AND DATA PROTECTION

We do not maintain a formal cybersecurity risk management framework.

We do not employ dedicated cybersecurity personnel and rely on third-party service providers. A cybersecurity breach could result in operational disruption, reputational damage, regulatory scrutiny, or financial loss.

GENERAL RISK FACTORS

Economic conditions may adversely affect our ability to raise capital.

Adverse economic conditions, including inflation, rising interest rates, and market volatility, may reduce investor appetite for speculative investments and impair our ability to obtain financing.

An investment in our common stock is highly speculative.

Given our development-stage status, lack of revenue, minimal liquidity, significant liabilities, material weakness in internal controls, governance limitations, regulatory uncertainty, and dependence on future financing, an investment in our common stock is highly speculative and may result in the loss of your entire investment.

We may become subject to securities class action litigation or stockholder derivative actions, which could result in substantial costs and diversion of management attention.

Companies with limited operating histories, development-stage business models, minimal revenues, recurring losses, or significant stock price volatility frequently become the target of securities class action litigation or stockholder derivative lawsuits. Given our development-stage status, going-concern uncertainty, dependence on future financing, related-party transactions, material weakness in internal control over financial reporting, and limited trading liquidity, we may be particularly susceptible to such litigation.

Securities class action lawsuits are often brought against companies following periods of stock price volatility, reverse stock splits, dilutive financings, restatements, regulatory developments, or public disclosures regarding internal control deficiencies. Such lawsuits typically allege violations of federal securities laws, including claims under Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, or under Sections 11 and 12 of the Securities Act in connection with securities offerings. Even if such claims are without merit, defending against them can be costly, time-consuming, and disruptive to our operations.

In addition, we may become subject to stockholder derivative actions alleging breach of fiduciary duties by our officers or director, particularly given our governance structure, related-party transactions, and development-stage operations. Such actions may seek monetary damages, corporate governance changes, or other equitable relief.

The costs of defending securities litigation or derivative actions may be significant and may exceed the limits of our directors’ and officers’ liability insurance coverage, if any. Adverse judgments, settlements, or regulatory findings could materially adversely affect our financial condition, liquidity, reputation, and ability to raise capital. Furthermore, even the initiation of litigation could result in negative publicity, investor concern, and diversion of management attention from our business.

If we are unable to successfully defend against such claims or manage associated costs, our business, financial condition, and results of operations could be materially adversely affected.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

We did not issue any equity securities for the quarter ended ~~October~~April 3130, ~~2023~~2024.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

11 Table of Contents

Item 6. Exhibits

The following documents are filed as part of this report:

31.1		Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)
Exhibit Number		Description
32.1		Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002
(31)		Rule 13a-14(a)/15d-14(a) Certification
101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
31.1/31.2*		Certification of Chief Executive Officer and Chief Executive Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
(32)		Section 1350 Certification
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
32.1/32.2*		Certifications of Chief Executive Officer and Chief Executive Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101*		Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q.
101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document.
104*		Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in Exhibit 101 Inline XBRL Document Set.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

12 * ~~Table~~Filed ~~of Contents~~herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	~~VITASPRING BIOMEDICAL CO., LTD.~~	VITASPRING BIOMEDICAL CO., LTD.
Date: January 29, 2026	/s/ Ssu-Chuan Lai
Date: April 02, 2026		/s/ Ssu-Chuan Lai
	~~Ssu-Chuan Lai~~	Ssu-Chuan Lai
	President, Chief Executive Officer, and Chief Financial Officer
		President, Chief Executive Officer, and Principal Financial Officer

1318

Filing Compare · VITASPRING BIOMEDICAL CO. LTD.